May 2020 vidcast: Pharmasset acquisition by Gilead
Behind one of the most important recent pharmaceutical transactions
Remdesivir has once again put pharmaceutical giant Gilead in the media spotlight for its ability to reduce the symptoms of COVID-19
In this vidcast, Professor Dominique Jacquet goes back a bit in the history of Gilead to analyse the acquisition that the giant made of the start-up Pharmasset. At the time, Pharmasset had developed a molecule that cured Hepatitis C.
The transaction was a big deal, as was the price of the drug once it was acquired by Gilead. The vidcast talks as much about financial value as it does about reputational value.